Category

Stocks

Hot Stocks

Dividend Stocks: 25 New and Noteworthy Increases for Yield Seekers

Dividend stocks are off to a strong start in 2014. And with S&P 500 companies sitting on huge cash piles – $1.25 trillion for non-financial firms – companies can afford to sweeten payouts.

This follows 2013's generous year in which cumulative dividend hikes amounted to a hefty $56.7 billion.

This is great news for income-starved investors who continue to gravitate toward dividend-paying stocks, as money market funds yield a paltry 0.01%.

To continue reading, please click here...

Investing Tips

Three Shocking Market Predictions for 2014… And the Evidence to Prove Them

Each January, we hear a chorus of pundits making predictions about where the markets will go in the 12 months ahead. The number and volume level of the "predictions" is matched only by the utter lack of evidence to back them up.

These talking heads will be the first to shout "I told you so!" But when they get it wrong, well… the silence is deafening. Their predictions are of little use to us.

But predictions themselves can be very useful. Making a well-reasoned prediction can be a great way to crystallize your thinking on important issues. It's also a good filter that can help you select which trends and sectors to embrace – and which to avoid – over the year ahead.

With this in mind, I have three predictions, all backed by compelling evidence, that will surprise you... and help you make a lot of money this year.

Top News

General Electric's (NYSE: GE) Earnings Report: Here's the Most Important Number for Investors

General Electric Co. (NYSE: GE) will report earnings Friday morning, and analysts are projecting earnings per share of $0.53 on revenue of $40.2 billion.

The $0.53 EPS estimate is a 20% increase from General Electric's 2012 Q4 earnings. Likewise, the revenue estimate is 2% higher than the $39.3 billion revenue GE reported in the previous year.

To continue reading, please click here...

Biotech

The New Way to Make Big Money in Biotech

Editor's Note: Today, we'd liked to welcome Ernie Tremblay to Money Morning. He's been providing his bioscience research to our premium services for over a year now and we couldn't be more thrilled with the results, including a 457% gain on one of his recommendations. So here's how Ernie does it…

Traditional pharmaceutical blockbusters like Pfizer's Lipitor treat millions of patients at relatively low cost. It's a high-volume business model that has kept the pharmaceutical industry afloat for a long, long time. But over the past decade, out of necessity, a new model has taken the industry by storm.

As big moneymakers, like Lipitor, reach the "patent cliff," their intellectual rights protection are evaporating, and generic drug makers are taking over their markets.

Big Pharma needs fresh drugs to take the place of those they're losing. But replacing these products with new ones is expensive. Most experts agree that it takes about $800M in capitalized costs to develop a single new drug. And frankly, the "easier" medical riddles, like treating high LDL cholesterol, have mostly been solved. The remaining tough ones, like cancer and Alzheimer's, will drive costs even higher.

So how do the major pharmaceutical companies meet the challenge? By letting small, smart start-up biotechs do the R&D legwork on new drugs, then either making distribution deals with them or buying the small companies out.

Here's what makes this new approach so lucrative for investors...

LNG

Cheniere (LNG) Stock Is Still the Industry Leader

Cheniere (LNG) stock has climbed 126% over the past year – and we believe there's a lot more to come.

Houston-based Cheniere Energy Inc. (NYSE MKT: LNG) is the biggest name in liquefied natural gas (LNG) exporting. It was the first company that the U.S. Energy Department granted approval for exporting to countries that do not have a Free Trade Agreement with the United States.

Cheniere's head start on competitors gives it what Forbescalled a near-monopoly for the next few years.

To continue reading, please click here...

Hot stocks

What's Next For Tech Stocks in 2014

Tech stocks like Google Inc. (Nasdaq: GOOG), Amazon.com Inc. (Nasdaq: AMZN), Netflix Inc. (Nasdaq: NFLX), and Apple Inc. (Nasdaq: AAPL) are "where the action is" in tech. They make the most money and create the most innovative products and services.

These tech stocks also serve as good benchmarks for how the whole industry is performing.

To watch the video, please click here...

Penny Stocks

Pot Penny Stocks Are Up as Much as 1,210% – Here's How to Invest Now

GreenGro Technologies Inc. (OTC: GRNH) is up 1,210% (after having risen as much as 2,100%), Cannibis Science Inc. (OTC: CBIS) is up 183%, and Hemp Inc. (OTC: HEMP) is up 359%.

Hemp Chief Executive Officer Bruce Perlowin told Bloomberg News investors in pot penny stocks are looking for "the next Microsoft."

"The demand for marijuana is insatiable," said Perlowin. "You have a feeding frenzy for the birth of a new industry."

This is the kind of growth opportunity that comes along only once in a generation...

Top News

Why Google (Nasdaq: GOOG) Bought Nest

Google Inc. (Nasdaq: GOOG) announced Tuesday that it would be purchasing Nest Labs for $3.2 billion. Nest is known for developing Internet-connected, or "smart," thermostats and smoke detectors.

GOOG stock currently trades just north of $1,140, and has posted a gain of more than 30% in the past three months. Will adding everyday products like Nest's thermostats to its portfolio make a difference for investors?

To watch the video, click here...

Hot Stocks

Best Stocks to Buy Now: A Money Morning Weekly Recap

Best stocks to buy for the week ending Jan. 10, 2014: We're barely two weeks into 2014 and the U.S. Federal Reserve is already dominating headlines – and sending ripples through the markets.

Janet Yellen was confirmed last week as the central bank's new chairwoman, followed by release of the highly anticipated minutes from the Fed's last meeting. And the Fed was again in focus Friday as the disconcerting December jobs report left the central bank's decision to taper its bond-buying program in question.

To continue reading, please click here...